Quest Diagnostics Incorporated (DGX)
NYSE: DGX · Real-Time Price · USD
234.40
-1.64 (-0.69%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Quest Diagnostics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,560 | 11,035 | 9,872 | 9,252 | 9,883 | 10,788 | |
Revenue Growth | 9.87% | 11.78% | 6.70% | -6.39% | -8.39% | 14.32% |
Cost of Revenue | 7,723 | 7,357 | 6,599 | 6,186 | 6,431 | 6,571 |
Gross Profit | 3,837 | 3,678 | 3,273 | 3,066 | 3,452 | 4,217 |
Selling, General & Admin | 2,001 | 1,920 | 1,731 | 1,630 | 1,838 | 1,723 |
Amortization of Goodwill & Intangibles | 151 | 154 | 127 | 108 | 120 | 103 |
Other Operating Expenses | -1 | -1 | 1 | 12 | -3 | -2 |
Operating Expenses | 2,151 | 2,073 | 1,859 | 1,750 | 1,955 | 1,824 |
Operating Income | 1,686 | 1,605 | 1,414 | 1,316 | 1,497 | 2,393 |
Interest Expense | -269 | -277 | -226 | -163 | -148 | -152 |
Interest & Investment Income | 13 | 13 | 25 | 11 | 10 | 1 |
Earnings From Equity Investments | 29 | 42 | 19 | 26 | 44 | 78 |
Other Non Operating Income (Expenses) | 31 | 26 | 18 | 20 | -55 | 55 |
EBT Excluding Unusual Items | 1,490 | 1,409 | 1,250 | 1,210 | 1,348 | 2,375 |
Merger & Restructuring Charges | -45 | -83 | -50 | -54 | -69 | -12 |
Gain (Loss) on Sale of Investments | -1 | - | - | - | - | 314 |
Legal Settlements | -22 | -22 | - | - | - | - |
Other Unusual Items | 11 | 56 | -6 | - | - | - |
Pretax Income | 1,433 | 1,360 | 1,194 | 1,156 | 1,279 | 2,677 |
Income Tax Expense | 320 | 314 | 273 | 248 | 264 | 597 |
Earnings From Continuing Operations | 1,113 | 1,046 | 921 | 908 | 1,015 | 2,080 |
Net Income to Company | 1,113 | 1,046 | 921 | 908 | 1,015 | 2,080 |
Minority Interest in Earnings | -51 | -54 | -50 | -54 | -69 | -85 |
Net Income | 1,062 | 992 | 871 | 854 | 946 | 1,995 |
Preferred Dividends & Other Adjustments | 4 | 4 | 5 | 4 | 4 | 7 |
Net Income to Common | 1,058 | 988 | 866 | 850 | 942 | 1,988 |
Net Income Growth | 11.96% | 14.09% | 1.88% | -9.77% | -52.62% | 39.51% |
Shares Outstanding (Basic) | 110 | 111 | 111 | 112 | 116 | 125 |
Shares Outstanding (Diluted) | 113 | 113 | 113 | 113 | 118 | 128 |
Shares Change | -0.88% | - | - | -4.24% | -7.81% | -5.88% |
EPS (Basic) | 9.62 | 8.90 | 7.80 | 7.59 | 8.12 | 15.90 |
EPS (Diluted) | 9.42 | 8.75 | 7.69 | 7.49 | 7.97 | 15.55 |
EPS Growth | 12.83% | 13.78% | 2.67% | -6.02% | -48.75% | 48.52% |
Free Cash Flow | 1,349 | 1,359 | 909 | 864 | 1,314 | 1,830 |
Free Cash Flow Per Share | 11.99 | 12.03 | 8.04 | 7.65 | 11.14 | 14.30 |
Dividend Per Share | 3.320 | 3.200 | 3.000 | 2.840 | 2.640 | 2.480 |
Dividend Growth | 7.10% | 6.67% | 5.63% | 7.58% | 6.45% | 10.71% |
Gross Margin | 33.19% | 33.33% | 33.15% | 33.14% | 34.93% | 39.09% |
Operating Margin | 14.59% | 14.54% | 14.32% | 14.22% | 15.15% | 22.18% |
Profit Margin | 9.15% | 8.95% | 8.77% | 9.19% | 9.53% | 18.43% |
Free Cash Flow Margin | 11.67% | 12.31% | 9.21% | 9.34% | 13.30% | 16.96% |
EBITDA | 2,266 | 2,175 | 1,907 | 1,755 | 1,934 | 2,801 |
EBITDA Margin | 19.60% | 19.71% | 19.32% | 18.97% | 19.57% | 25.96% |
D&A For EBITDA | 580 | 570 | 493 | 439 | 437 | 408 |
EBIT | 1,686 | 1,605 | 1,414 | 1,316 | 1,497 | 2,393 |
EBIT Margin | 14.59% | 14.54% | 14.32% | 14.22% | 15.15% | 22.18% |
Effective Tax Rate | 22.33% | 23.09% | 22.86% | 21.45% | 20.64% | 22.30% |
Advertising Expenses | - | 35 | 28 | 31 | 74 | 78 |